Sellas snags Nasdaq listing in reverse merger with Galena by Nick Paul Taylor Tuesday, August 8, 2017 The deal gives Sellas a route to public investors as it seeks to guide its WT1-targeting drug through phase 3 trials in AML and mesothelioma.
Working through mounting issues, Galena cuts staff, seeks ‘alternatives’ by Ben Adams Wednesday, July 12, 2017 Galena is engaging in “extensive interactions with numerous companies" seeking “strategic alternatives” that could include a merger, a reverse merger, asset sale, combo and/or a spinoff.
